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Introduction
High-risk stage II colon cancer is defined in European and
American guidelines as the presence of at least one of the
following high-risk factors: T4 stage, tumor differentiation
grade 3, bowel obstruction or perforation, presence of lym-
phovascular invasion (LVI), or <12 investigated lymph nodes
[1–3]. Perineural invasion (PNI), high tumor budding and
compromised surgical margin are also strong predictors of
disease recurrence [3–6]. Circulating tumor DNA is a promis-
ing novel biomarker in colorectal cancer (CRC) and could be
the most influential prognostic marker after radical surgery,
but its predictive value has not yet been established [7–9].
A disease-free survival benefit from fluoropyrimidine-
based adjuvant chemotherapy in stage II colon cancer has
been demonstrated in the Quasar trial [10] and in systematic
reviews, with an OS benefit in some [10,11] but not statistic-
ally significant in all [12–14]. However, the inclusion and def-
inition of high-risk stage II patients varies between studies
and thus also the efficacy. Patients with stage II CRC harbor-
ing high microsatellite instability (MSI) show a good progno-
sis compared to patients with proficient mismatch repair and
do not benefit from fluoropyrimidine-based adjuvant chemo-
therapy [12,15].
Several studies on stage II colon cancer have shown that
each of these high-risk factors has a distinct impact on sur-
vival, and the relapse risk rises with the number of high-risk
factors [16–19]. The relative benefit of adjuvant chemother-
apy also varies depending on the high-risk factor [18–20].
Our aim was to assess the significance of each high-risk
factor in stage II colon cancer and to develop an easily
adaptable risk score, which could predict cancer-specific sur-
vival (CSS), with or without adjuvant chemotherapy.
Material and methods
Ethics
Auria Biobank and Clinical Informatics collects tissue samples
and clinical data from patients treated at the Turku
University Hospital and Satakunta Central Hospital districts in
Finland. An independent validation cohort was obtained
from the data registry at the department of oncology at
Tampere University Hospital. Both Auria and Tampere obtain
clinical data directly from operational electronic health
record systems. The current study was approved by the
Scientific Steering Committee of Auria Biobank, and research
permission was granted by the Institutional Review Boards of
Turku, Satakunta and Tampere hospitals.
Study population
All patients diagnosed with CRC during 2004–2017 in Turku
University Hospital and during 2004–2012 in Satakunta
Central Hospital were identified as described earlier [21]. The
validation cohort from Tampere was obtained differently,
including all patients diagnosed with CRC who were referred
to the department of Oncology during 2010–2018. pStage II
colon cancers were identified according to the TNM 2010
system, excluding 65 patients with known MSI or OS
<1month. MSI immunohistochemistry was widely imple-
mented in Turku region starting from 2015. R1 resection was
defined as proximal, lateral or distal margin of 1mm. Right-
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sided colon cancer included tumors from the cecum to the
transversal colon and left-sided from the splenic flexure to
the sigmoid colon. Patients were classified having 0, 1 or 2þ
comorbidities according to Charlson comorbidity classifica-
tion [22], using hospital ICD-10 codes.
Adjuvant chemotherapy data were available for Turku and
Tampere cohorts. By our definition adjuvant therapy was
considered given if at least three months of fluoropyrimi-
dine- and/or oxaliplatin-based chemotherapy was completed.
Developing the risk score
An experimental risk score (RS) was created by the authors
for stage II colon cancer. First, univariable Cox regression
analysis for CSS was performed for each of the high-risk fac-
tors present: T4 stage, obstruction/perforation, <12 lymph
nodes investigated, grade 3 tumor, R1 resection and pres-
ence of LVI and/or PNI. The electronic system reports LVI/PNI
as either positive or negative and cannot distinguish
between them. Second, since it has been shown that each
high-risk factor affects survival in different magnitude
[17–20], each high-risk factor was weighted based on Cox
hazard ratio (HR), modified from the method used by
Charlson [22]: Non-significant factors yield 0 points. Factors
with HR 1.5–2.49 yield 1 point, factors with HR 2.5–3.49 yield
2 points, and those with HR 3.5 or more 4 points. These
points are added together to calculate the RS. Third, RS was
compared to the traditional practice where each high-risk
factor yields 1 point [16].
Statistics
The primary endpoint was CSS, defined as the period from
diagnosis by a pathologist to date of death due to CRC
(ICD10 codes C18–C20) or censored at the end of the follow-
up in December 2018 or at time of non-CRC death. Date and
cause of death was verified from Statistics Finland, an inde-
pendent national statistical registry.
The HRs were analyzed with Cox regression using the
enter method with 95% confidence interval (CI). High-risk
factors with a p-value of <.05 were included in the RS
model. The variances were analyzed either with Tukey’s
ANOVA or Pearson’s chi-square test. Area under the receiver-
operator curve (AUC or AUROC) was calculated assuming a
positive correlation with high RS and short CSS. Survival esti-
mates were calculated with the Kaplan-Meier log-rank
method. All statistical analyses were performed with SPSS
Statistics version 26 (IBM, Chicago, IL) software.
Results
Study population
Patients with pStage II colon cancer from Turku (N¼ 485)
and Satakunta (N¼ 219) cohorts were used for model train-
ing. A separate Tampere cohort with 183 pStage II colon can-
cer patients was used for model validation (Table 1). The
median follow-up time was 5.9 years in the training cohort
and 3.5 years in the validation cohort. Patients in the valid-
ation cohort were younger (p < .001) and had received more
adjuvant chemotherapy (p ¼ .006). LVI/PNI was not routinely
assessed in Satakunta cohort (Table 1).
Risk score predicts cancer-specific survival in stage II
Colon cancer
In the training cohort, a T4 tumor, presence of LVI/PNI,
tumor obstruction or perforation, <12 lymph nodes investi-
gated and R1 resection were negatively associated with CSS.
Specifically, R1 resection yielded 4 points (HR 9.8 (3.9–24.9),
p < .001), T4 tumor 2 points (HR 2.6 (1.6–4.2), p < .001),
obstruction/perforation 2 points (HR 3.0 (2.0–4.7), p < .001),
inadequate lymph node sampling 1 point (HR 1.8 (1.2–2.7), p
¼ .006) and LVI/PNI 1 point (HR 2.0 (1.0–3.9), p ¼ .04). Points
were added together to form the RS. Tumor grade was not
associated with CSS, HR 0.8 (0.6–1.3), and neither was mucin-
ous histology as compared to non-mucinous histology.
A high RS predicted shorter CSS in the training cohort
(Figure 1(A,C), AUC 0.72) and in the validation cohort (Figure
1(B,C), AUC 0.69). Median RS in both training and validation
cohorts was 1 (range 0–6). For comparison, simply adding
Table 1. Demographics of the stage II colon cancer study populations.
Training cohort Validation cohort
Number of patients 704 183
Female 352 (50%) 86 (47%)




2 or more 12% 13%
Right-sided primary 346 (49%) 101 (55%)
Known microsatellite stability 80 Not available
Adjuvant therapy for at least 3months 102 out of 485 patients (21%)b 57 (30%)
High-risk factors
T4 99/704 (14%) 76/183 (41%)
Gradus 3 75/689 (11%) 30/149 (20%)
LVI/PNI 88/428 (21%) 101/160 (63%)
<12 lymph nodes dissected 239/703 (35%) 7/153 (5%)
Obstruction/perforation 120/704 (17%) 14/183 (8%)
R1 resection (1mm) 7/704 (1%) 4/183 (2%)
aAccording to Charlson comorbidity classification.
bSatakunta adjuvant chemotherapy data was not available.
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the number of high-risk factors together from the six afore-
mentioned high-risk factors, resulted in an AUC 0.68 in the
training cohort, and no CSS difference was observed
between patients with 2 or 3þ high-risk factors (Figure 1(D)).
Comparing RS 0–1 and 2–6 AUC was 0.68.
To minimize the effect of missing data (Table 1) multivari-
able analysis was performed (Supplementary Table 1). A T4
tumor, presence of LVI/PNI, lymph node sampling <12 and
R1 resection remained as independent prognostic factors,
while tumor obstruction/perforation did not. Additionally,
gender, presence of comorbidities and tumor location in left
or right colon did not affect CSS, but age 75 years was
independently associated with short CSS (HR 2.5 (1.5–4.3)).
Adjuvant chemotherapy
Patients who had received at least 3months of chemother-
apy and were aged <80 years were pooled from Turku and
Tampere cohorts for this analysis (N¼ 510). Overall, in stage
II colon cancer CSS did not differ in those who had received
adjuvant treatment compared to those who had not
(Supplementary Figure 1A). Only in patients with RS 2 or
more, a longer CSS was observed in patients who had
received adjuvant chemotherapy (HR 0.4 (0.2–0.9), p ¼ .02,
Supplementary Figure 1B). Those who had received adjuvant
chemotherapy were 6 years younger and had less
comorbidities.
Discussion
Numerous studies have been conducted to identify which
patients with stage II colon cancer are at high risk of recur-
rence and would benefit from adjuvant chemotherapy, but
the definition of high-risk stage II CRC is variable
[10–14,17–20]. Our study is in line with previous findings
[16–19] showing that a higher number of high-risk factors in
stage II colon cancer increases the risk of death from CRC,
and we show that this is independent of tumor grade, gen-
der or comorbidities. Here we introduce a RS which can be
easily calculated and incorporated into clinical trial design to
assess the risk of death from colon cancer.
Disease recurrence nomograms for colon cancer have been
developed, but the nomograms include stage II–III patients and
rely on complex calculation procedures with AUC values of
0.64–0.77 [23–25] or biomarkers KRAS and BRAF with AUC
0.66–0.74 [26]. Our RS is easy to calculate and has comparable
predictive accuracy (0.72) to these models, even though AUC
<0.80 is generally considered as limited diagnostic accuracy.
CSS was chosen as the primary endpoint, since it could be veri-
fied from an independent source and is more precise than OS.
The RS performed equally well in both training and validation
cohorts, even though the validation cohort was not formally
powered and the inclusion criteria for the cohorts were differ-
ent; the training cohort was biobank-based from consecutively
operated CRC patients and the validation cohort included
selected patients referred for oncologist for possible adjuvant
chemotherapy. This may explain the younger age and higher
Figure 1. Ten-year cancer-specific survival according to the risk score (RS). (A) Training cohort of 704 patients. (B) Validation cohort of 183 patients. (C) Prediction
accuracy of the training and validation cohorts. (D) For comparison, traditional practice using the training cohort, where the number of high-risk factors are
added together.
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frequency of T4 and LVI positive tumors in the valid-
ation cohort.
Regular multidisciplinary meetings began during 2004 in
Turku region and during 2007 in Tampere region, thus
before the current study. In Satakunta the meetings were
irregular. At that time in Turku and Satakunta, adjuvant
chemotherapy was recommended if at least one of any high-
risk factor was present in stage II colon cancer [1], while in
Tampere at least two high-risk factors were preferred for
adjuvant therapy.
Our study did not support tumor differentiation grade as
a prognostic factor for CSS. Similar findings have been
reported previously for stage II CRC [7,18,24] while in larger
analyses with stage II–III CRCs, tumor grade 3 has remained
as a significant prognostic factor [16]. Grading of CRC may
be somewhat inconsistent based on known interobserver
variation bias, which could affect especially older tumor sam-
ples prior to the WHO 2010 classification [27]. This issue has
been addressed in the latest 2019 classification where CRC is
graded as low or high. The results concerning R1 resection
should be interpreted with caution, since some T3R1 tumors
may be confused with T4aR0 tumors [6].
It was of great interest to observe how the relative benefit
of adjuvant chemotherapy improved as RS increased. CSS
benefit from adjuvant therapy was observed only in RS 2–6
patients. Our retrospective study was designed to predict
survival with standard adjuvant treatments used in the hospi-
tals of the study, therefore causing selection bias since treat-
ment allocation was not randomized. In the future, new
emerging biomarkers including circulating tumor DNA [7–9],
could alongside our RS model further improve the tailoring
of adjuvant chemotherapy in stage II colon cancer.
In conclusion, our validated RS model predicted survival
comparably to other models and nomograms reported previ-
ously, without the need for additional biomarkers or complex
mathematics. However, due to limited number of patients in
the current study, these results should be reproduced in a
larger adequately powered prospective study setting. The RS
could easily be adapted to clinical trial design by using a
structured pathology report.
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